Exercise of Option Year SPE2D217D0060P00006
ID: SPE2D217D0060Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/599bf13b103e49739fe9cc68d2590112/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is exercising the option for the Hydrochlorothiazide National Contract. Hydrochlorothiazide is a medication used to treat high blood pressure and fluid retention. This procurement is for the supply of Hydrochlorothiazide, which is a medical and surgical instrument, equipment, and supply. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 2157376877.

    Point(s) of Contact
    Denise Taubman
    (215) 737-6877
    denise.taubman@dla.mil
    Lifecycle
    Title
    Type
    EXERCISE OF OPTION HYDROCHLOROTHIAZIDE NATIONAL CONTRACT
    Currently viewing
    Special Notice
    Similar Opportunities
    Telmisartan Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product essential for various medical applications, under Solicitation No. SPE2D2-24-R-0015. The contract aims to secure a reliable supply of these tablets in multiple dosages over several years, emphasizing compliance with federal regulations, including the necessity for a Subcontracting Plan for large businesses and adherence to various Federal Acquisition Regulation (FAR) clauses. Interested contractors should note that the submission deadline has been extended to February 28, 2025, at 3:00 PM EST, and are encouraged to contact Courtney Hunter-Stangler at Courtney.Hunter-Stangler@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    6505--Hydroxychloroquine SO4 Tablets
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) for the procurement of Hydroxychloroquine SO4 Tablets, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will cover an estimated annual requirement of 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets, with a contract period of one year and four optional one-year extensions. This procurement is critical for maintaining essential medications within veteran and federal healthcare programs. Interested parties should monitor SAM.gov for updates and direct inquiries to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov or (708) 786-4980, with submissions due by March 26, 2025.
    Doxycycline Hyclate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    MODIFICATION TO ENALAPRIL NATIONAL CONTRACT
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking a modification to the ENALAPRIL NATIONAL CONTRACT. This modification aims to incorporate additional clauses into the existing contract. The ENALAPRIL NATIONAL CONTRACT is typically used for the procurement of enalapril, a medication used to treat high blood pressure and heart failure. The modification will ensure that the contract includes all necessary terms and conditions for the procurement of enalapril. For more information, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.
    Fluconazole - SPE2D221-D-0125-P00012 - Final Option Notice
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), has issued a special notice regarding the contract modification for Fluconazole under contract number SPE2D221-D-0125-P00012. This modification announces the exercise of the final option for the procurement of this pharmaceutical product, which is critical for various medical applications within military healthcare. Interested parties can reach out to the primary contact, Courtney Hunter-Stangler, at Courtney.Hunter-Stangler@dla.mil or by phone at 215-737-6845, or to the secondary contact, Jason Wray, at jason.wray@dla.mil or 215-737-0614, for further details regarding this opportunity.
    Finasteride Tablets
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Lansoprazole Capsules
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting offers for the procurement of Lansoprazole DR 30MG capsules, a pharmaceutical product essential for treating various gastrointestinal conditions. This solicitation outlines the requirements for contractors to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS), emphasizing compliance with Federal Acquisition Regulation (FAR) clauses and ethical business practices. The procurement is critical for maintaining the supply of necessary medications to support military personnel, ensuring adherence to stringent quality and legal standards. Interested contractors should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil, with submissions due by the specified deadline in the solicitation document.
    Chlorhexidine Gluconate (CHG) Applicators, Procedural
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking qualified vendors to supply Chlorhexidine Gluconate (CHG) Applicators, Procedural, as part of a Combined Synopsis/Solicitation. Vendors are required to submit detailed pricing and product specifications, including compliance with the Qualified Suppliers List (QSL) and adherence to the Distribution and Pricing Agreement (DAPA), to support Military Treatment Facilities (MTFs) across various branches of the military. This procurement action is crucial for standardizing medical supplies and ensuring efficient healthcare delivery within the defense sector, with an estimated annual demand valued at approximately $812,275.77. Interested vendors must submit their proposals by March 6, 2025, and can direct inquiries to Mr. Arthur B. Redmond at arthur.b.redmond.ctr@health.mil or David Sheaffer at david.v.sheaffer.ctr@health.mil.